- Home
- ESEA vs JSPR Comparison
ESEA vs JSPR Comparison
Compare ESEA & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | JSPR |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Greece | United States |
| Employees | N/A | 22 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.2M | 14.9M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ESEA | JSPR |
|---|---|---|
| Price | $71.63 | $0.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $62.00 | $15.50 |
| AVG Volume (30 Days) | 65.4K | ★ 620.1K |
| Earning Date | 06-17-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.60 | $0.42 |
| 52 Week High | $78.76 | $7.19 |
Technical Indicators
Market Signals| Indicator | ESEA | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 24.52 |
| Support Level | $52.53 | N/A |
| Resistance Level | $74.76 | $1.02 |
| Average True Range (ATR) | 2.64 | 0.09 |
| MACD | 0.48 | -0.02 |
| Stochastic Oscillator | 91.48 | 8.69 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.